Sugi Predict

Sugi Predict / Targets / PIKFYVE

PIKFYVE

1-phosphatidylinositol 3-phosphate 5-kinase · Q9Y2I7 · PIKFYVE on Sugi Atlas →

7,167 patent compounds predicted against PIKFYVE, 4,800 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL423724 SCHEMBL423724 0.55 12/20
SCHEMBL423725 SCHEMBL423725 0.55 12/20
SCHEMBL426828 SCHEMBL426828 0.51 12/20
SCHEMBL426829 SCHEMBL426829 0.51 12/20
SCHEMBL424200 SCHEMBL424200 0.50 12/20
SCHEMBL424201 SCHEMBL424201 0.50 12/20
SCHEMBL429158 SCHEMBL429158 0.66 11/20
SCHEMBL429159 SCHEMBL429159 0.66 11/20
SCHEMBL428807 SCHEMBL428807 0.65 11/20
SCHEMBL428808 SCHEMBL428808 0.65 11/20
SCHEMBL424853 SCHEMBL424853 0.64 11/20
SCHEMBL424854 SCHEMBL424854 0.64 11/20
SCHEMBL426675 SCHEMBL426675 0.60 11/20
SCHEMBL426676 SCHEMBL426676 0.60 11/20
SCHEMBL425357 SCHEMBL425357 0.56 11/20
SCHEMBL425358 SCHEMBL425358 0.56 11/20
SCHEMBL912404 SCHEMBL912404 0.54 11/20
SCHEMBL912405 SCHEMBL912405 0.54 11/20
SCHEMBL912255 SCHEMBL912255 0.52 11/20
SCHEMBL912256 SCHEMBL912256 0.52 11/20

Clinical trials — most relevant to PIKFYVE by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway PHASE4COMPLETED
Addition of Everolimus to Standard of Care in Carcinoma Gallbladder PHASE2/PHASE3RECRUITING
Efficacy of Lithium Against Chemotherapy Induced Neutropenia in Breast Cancer Patients PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome PHASE1/PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
STAR Cape+BKM120 MBC With Brain Met PHASE2COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer PHASE1/PHASE2RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Trial of Metformin for Colorectal Cancer Risk Reduction for History of Colorectal Adenomas and Elevated BMI PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers PHASE1COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
Nilotinib in Huntington's Disease PHASE1UNKNOWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events nanCOMPLETED
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Association of Autophagy-related Genes ,LncRNA and SNPs With Colorectal Cancer in Egyptian Population nanCOMPLETED
Protein Intake and Step Reduction in Older Adults nanCOMPLETED
Glycine and Magnesium+Thiamine for the Treatment of Primary Ciliary Dyskinesia nanRECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML) nanCOMPLETED
Study of Proteus Syndrome and Related Congenital Disorders nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a PIKFYVE binder may also engage these)

ProteinNameSimilarity
Q9Z1T6 — 1.000 Q9Z1T6 →
A6QP06 — 0.998 A6QP06 →
Q92539 — 0.998 Q92539 →
A8KBE0 — 0.997 A8KBE0 →
Q99PI5 — 0.997 Q99PI5 →
B2GUY1 — 0.996 B2GUY1 →
Q2PFD7 — 0.996 Q2PFD7 →
A2AHC3 — 0.996 A2AHC3 →
Q1LYM3 — 0.995 Q1LYM3 →
MAP3K13 Mitogen-activated protein kinase kinase kinase 13 0.995 landscape →
Q9D3S3 — 0.995 Q9D3S3 →
Q60610 — 0.995 Q60610 →
Q8WML3 — 0.995 Q8WML3 →
Q9DDT2 — 0.995 Q9DDT2 →
D4AEC2 — 0.995 D4AEC2 →
Q9BQK8 — 0.995 Q9BQK8 →
Q7ZUL9 — 0.995 Q7ZUL9 →
G5EFD2 — 0.995 G5EFD2 →
BPTF Nucleosome-remodeling factor subunit BPTF 0.995 landscape →
Q91ZP3 — 0.995 Q91ZP3 →
Q8BMD7 — 0.995 Q8BMD7 →
Q6IVY4 — 0.994 Q6IVY4 →
Q17QK1 — 0.994 Q17QK1 →
Q5JCS6 — 0.994 Q5JCS6 →
Q6DDJ5 — 0.994 Q6DDJ5 →
Q8C0T5 — 0.994 Q8C0T5 →
Q9HCH5 — 0.994 Q9HCH5 →
Q14693 — 0.994 Q14693 →
Q2NKQ1 — 0.994 Q2NKQ1 →
PTPN13 Tyrosine-protein phosphatase non-receptor type 13 0.994 landscape →